<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14926">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00241644</url>
  </required_header>
  <id_info>
    <org_study_id>102248</org_study_id>
    <nct_id>NCT00241644</nct_id>
    <nct_alias>NCT00598468</nct_alias>
  </id_info>
  <brief_title>Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants</brief_title>
  <official_title>Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>South Africa: Medicines Control Council</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine if the GSK Biologicals' human rotavirus
      (HRV) vaccine (pooled HRV groups) given concomitantly with routine expanded program on
      immunisation (EPI) vaccinations can prevent severe rotavirus gastroenteritis (≥11 on the
      20-point Vesikari scoring system [Ruuska, 1990]) caused by the circulating wild-type RV
      strains during the period from 2 weeks after the last dose of HRV vaccine or placebo until
      Visit 5.

      The primary objective will be reached if the lower limit of the 95% confidence interval (CI)
      on vaccine efficacy is &gt;0%.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will have three groups: Rotarix 3-Dose Group, Rotarix 2-Dose Group and Placebo
      Group. Three-dose immunisation will be administered in healthy infants at approximately 6,
      10, and 14 weeks of age. Routine EPI vaccinations will be administered concomitantly with
      the study vaccines. This study will also evaluate immunogenicity and safety relative to the
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strain</measure>
    <time_frame>From 2 weeks after the last vaccine or placebo dose up to 1 year of age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain, Classified by Rotavirus Type</measure>
    <time_frame>From 2 weeks after the last vaccine or placebo dose up to 1 year of age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects presenting with three or more looser than normal stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.
Rotavirus types were G1 wild type (WT) and non-G1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain</measure>
    <time_frame>From 2 weeks after the last vaccine or placebo dose up to 1 year of age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain</measure>
    <time_frame>From the first vaccine or placebo dose up to 1 year of age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In South Africa, Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain</measure>
    <time_frame>From 2 weeks after the third dose of vaccine or placebo up to 1 year of age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Severe Gastroenteritis of Any Cause</measure>
    <time_frame>From 2 weeks after the last vaccine or placebo dose up to 1 year of age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects with gastroenteritis (three or more looser than normal stools or watery stools within a day) that scored ≥ 11 on the 20-point Vesikari scoring system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strain</measure>
    <time_frame>From 2 weeks after the last vaccine or placebo dose up to 1 year of age</time_frame>
    <safety_issue>No</safety_issue>
    <description>RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strains</measure>
    <time_frame>During the period from 2 weeks after the last dose of vaccine or placebo until study end</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strains</measure>
    <time_frame>During the period from 1 year of age to study end</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Episode Caused by the Circulating Wild-type RV Strains</measure>
    <time_frame>During the period from 2 weeks after the last dose of vaccine or placebo until study end</time_frame>
    <safety_issue>No</safety_issue>
    <description>RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Episode Caused by the Circulating Wild-type RV Strains</measure>
    <time_frame>During the period from 1 year of age to study end</time_frame>
    <safety_issue>No</safety_issue>
    <description>RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strains, Classified by Rotavirus Type</measure>
    <time_frame>During the period from 2 weeks after the last dose of vaccine or placebo until study end</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.
Rotavirus types were G1 wild type (WT) and non-G1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strains, Classified by Rotavirus Type</measure>
    <time_frame>During the period from 1 year of age to study end</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.
Rotavirus types were G1 wild type (WT) and non-G1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Events (AEs) or Serious Adverse Events (SAEs) Leading to Drop Out</measure>
    <time_frame>From the first dose of vaccine or placebo up to end of the study</time_frame>
    <safety_issue>No</safety_issue>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>From the first dose of vaccine or placebo up to end of the study</time_frame>
    <safety_issue>No</safety_issue>
    <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Anti-rotavirus Immunoglobulin A (IgA) Antibodies in Initially Seronegative Subjects</measure>
    <time_frame>One month after the last vaccine dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>An initially seronegative subject is a subject whose IgA antibody concentration was below the assay cut-off value of 20 Units per milliliter (U/mL) before administration of the first vaccine dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects</measure>
    <time_frame>One month after the last vaccine or placebo dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconverted subjects are defined as subjects with appearance of anti-rotavirus IgA antibody concentration ≥ 20 U/mL in subjects initially (i.e. prior to the first dose of vaccine or placebo) seronegative for rotavirus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Anti-rotavirus Immunoglobulin A (IgA) Antibodies</measure>
    <time_frame>One month after the last vaccine or placebo dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean concentrations are given as Units per milliliter (U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects</measure>
    <time_frame>One month after the last vaccine or placebo dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seropositive subjects are defined as subjects with anti-rotavirus IgA antibody concentration ≥ 20 U/mL.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2089</enrollment>
  <condition>Rotavirus Vaccines</condition>
  <arm_group>
    <arm_group_label>Rotarix 3-Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rotarix 2-Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received 3 doses of placebo given concomitantly with routine EPI vaccines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotarix™</intervention_name>
    <description>Two or Three doses, oral administration</description>
    <arm_group_label>Rotarix 3-Dose Group</arm_group_label>
    <arm_group_label>Rotarix 2-Dose Group</arm_group_label>
    <other_name>GSK Biologicals' HRV vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One or three doses, oral administration.</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_label>Rotarix 2-Dose Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol should be enrolled in the study.

          -  A male or female child between, and including, 5 and 10 weeks of age at the time of
             the first study vaccination.

          -  Written informed consent obtained from the parent or guardian of the subject who is
             of legal age

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  In South Africa, birth weight &gt; 2000 grams or if weight unknown, gestation period &gt;
             36 weeks.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned
             use during the study period.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product

          -  Planned administration of a vaccine not foreseen by the study protocol within 14 days
             before each dose of study vaccine(s) and ending 14 days after.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants since
             birth.

          -  History of use of experimental rotavirus vaccine.

          -  Previous routine vaccination except Bacille Calmette-Guérin (BCG), hepatitis B virus
             (HBV) and oral poliovirus (OPV) vaccination at birth

          -  Any clinically significant history of chronic gastrointestinal disease including any
             uncorrected congenital malformation of the gastrointestinal tract, intussusception or
             other medical condition determined to be serious by the investigator.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination

          -  History of allergic disease or reaction likely to be exacerbated by any component of
             the vaccine.

          -  Acute disease at the time of enrolment.

          -  Gastroenteritis within 7 days preceding the first study vaccine administration

          -  Previous confirmed occurrence of rotavirus gastroenteritis (RV GE).

          -  A family history of congenital or hereditary immunodeficiency.

          -  Administration of immunoglobulins and/or blood products since birth or planned
             administration during the study period.

          -  History of any neurologic disorders or seizures.

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by physical examination or laboratory screening
             tests.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Weeks</minimum_age>
    <maximum_age>10 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Malawi</country>
    <country>South Africa</country>
  </removed_countries>
  <reference>
    <citation>Madhi SA, Kirsten M, Louw C, Bos P, Aspinall S, Bouckenooghe A, Neuzil KM, Steele AD. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. Vaccine. 2012 Apr 27;30 Suppl 1:A44-51. doi: 10.1016/j.vaccine.2011.08.080.</citation>
    <PMID>22520136</PMID>
  </reference>
  <reference>
    <citation>Madhi S et al. Efficacy of the human rotavirus vaccine RIX4414 against rotavirus G2P[4]/g8p[4] strains in South African infants. Abstract presented at the 6th world congress of the World Society for Pediatric Infectious Diseases (WSPID), Buenos Aires, Argentina, 18-22 November 2009.</citation>
  </reference>
  <reference>
    <citation>Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, Han HH, Neuzil KM. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010 Jan 28;362(4):289-98. doi: 10.1056/NEJMoa0904797.</citation>
    <PMID>20107214</PMID>
  </reference>
  <reference>
    <citation>Nakagomi T, Nakagomi O, Dove W, Doan YH, Witte D, Ngwira B, Todd S, Duncan Steele A, Neuzil KM, Cunliffe NA. Molecular characterization of rotavirus strains detected during a clinical trial of a human rotavirus vaccine in Blantyre, Malawi. Vaccine. 2012 Apr 27;30 Suppl 1:A140-51. doi: 10.1016/j.vaccine.2011.09.119.</citation>
    <PMID>22520123</PMID>
  </reference>
  <reference>
    <citation>Cunliffe NA, Witte D, Ngwira BM, Todd S, Bostock NJ, Turner AM, Chimpeni P, Victor JC, Steele AD, Bouckenooghe A, Neuzil KM. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine. 2012 Apr 27;30 Suppl 1:A36-43. doi: 10.1016/j.vaccine.2011.09.120.</citation>
    <PMID>22520135</PMID>
  </reference>
  <reference>
    <citation>Cunliffe NA et al. Efficacy of Human Rotavirus Vaccine RIX4414 in Malawian Infants in the first two years of life. Abstract presented at the 6th African Rotavirus Symposium, Johannesburg, South Africa, 2‐3 August 2010.</citation>
  </reference>
  <reference>
    <citation>Steele D et al. Diverse circulating rotavirus strains during the first year of life in African infants. Abstract presented at 10th International symposium on dsRNA Viruses, Hamilton Island, QLD, Australia, 21-25 June 2009.</citation>
  </reference>
  <reference>
    <citation>Neuzil K et al. RIX4414 is protective against severe RVGE caused by diverse rotavirus serotypes during the first year of life in African infants. Abstract presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Disease (ESPID), Brussels, Belgium, 9-13 June 2009.</citation>
  </reference>
  <reference>
    <citation>Neuzil K et al. Immunogenicity of human rotavirus vaccine RIX4414 in South African and Malawian infants. Abstract presented at the 6th world congress of the World Society for Pediatric Infectious Diseases (WSPID), Buenos Aires, Argentina, 18-22 November 2009.</citation>
  </reference>
  <reference>
    <citation>Steele AD et al. Efficacy of human rotavirus vaccine, Rotarix™ against severe gastroenteritis caused by diverse circulating rotavirus strains in African infants. Abstract presented at the 7th World Congress for World Society for Pediatric Infectious Diseases (WSPID). Melbourne, Australia, 16-19 November 2011.</citation>
  </reference>
  <reference>
    <citation>Cunliffe N et al. Efficacy of human rotavirus vaccine RIX4414 in Africa during the first year of life. Abstract presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Disease (ESPID), Brussels, Belgium, 9-13 June 2009.</citation>
  </reference>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>April 11, 2013</lastchanged_date>
  <firstreceived_date>October 18, 2005</firstreceived_date>
  <firstreceived_results_date>June 18, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rotavirus gastroenteritis</keyword>
  <keyword>HRV vaccine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Only subjects from Malawi and from Cohort 2 South Africa were asked to continue the study for a second follow-up period (Year 2).</recruitment_details>
      <pre_assignment_details>Of the total of 4941 subjects enrolled in this study, 2 subjects were allocated a subject number but did not get any study vaccine administered. Hence, only 4939 subjects were considered as 'started'.
For the second follow-up period, as mentioned in the protocol the results are presented for Rotarix Pooled and Placebo Groups only.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rotarix 2-dose Group</title>
          <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
        </group>
        <group group_id="P2">
          <title>Rotarix 3-dose Group</title>
          <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
        </group>
        <group group_id="P3">
          <title>Placebo Group</title>
          <description>Subjects received 3 doses of placebo.</description>
        </group>
        <group group_id="P4">
          <title>Rotarix Pooled Group</title>
          <description>Subjects received 2 or 3 doses of Rotarix™ (rotavirus vaccine).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Efficacy Period (Year 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1647"/>
                <participants group_id="P2" count="1651"/>
                <participants group_id="P3" count="1641"/>
                <participants group_id="P4" count="3298"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1420"/>
                <participants group_id="P2" count="1383"/>
                <participants group_id="P3" count="1392"/>
                <participants group_id="P4" count="2803"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="268"/>
                <participants group_id="P3" count="249"/>
                <participants group_id="P4" count="495"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="91"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="81"/>
                <participants group_id="P4" count="133"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="142"/>
                <participants group_id="P3" count="116"/>
                <participants group_id="P4" count="258"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Return dates not reliable</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Vaccinated at regular clinic</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject's parent passed away</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Efficacy Period (Year 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="771"/>
                <participants group_id="P2" count="754"/>
                <participants group_id="P3" count="746"/>
                <participants group_id="P4" count="1525"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="710"/>
                <participants group_id="P2" count="697"/>
                <participants group_id="P3" count="682"/>
                <participants group_id="P4" count="1407"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="118"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="86"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consenting parent passed away</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rotarix 2-dose Group</title>
          <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
        </group>
        <group group_id="B2">
          <title>Rotarix 3-dose Group</title>
          <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
        </group>
        <group group_id="B3">
          <title>Placebo Group</title>
          <description>Subjects received 3 doses of placebo.</description>
        </group>
        <group group_id="B4">
          <title>Rotarix Pooled Group</title>
          <description>Subjects received 2 or 3 doses of Rotarix™ (rotavirus vaccine).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1647"/>
                <measurement group_id="B2" value="1651"/>
                <measurement group_id="B3" value="1641"/>
                <measurement group_id="B4" value="3298"/>
                <measurement group_id="B5" value="8237"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="6.3" spread="0.92"/>
                <measurement group_id="B2" value="6.4" spread="0.98"/>
                <measurement group_id="B3" value="6.4" spread="0.97"/>
                <measurement group_id="B4" value="6.4" spread="0.95"/>
                <measurement group_id="B5" value="6.4" spread="0.95"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="811"/>
                <measurement group_id="B2" value="839"/>
                <measurement group_id="B3" value="800"/>
                <measurement group_id="B4" value="1650"/>
                <measurement group_id="B5" value="4100"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="836"/>
                <measurement group_id="B2" value="812"/>
                <measurement group_id="B3" value="841"/>
                <measurement group_id="B4" value="1648"/>
                <measurement group_id="B5" value="4137"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strain</title>
        <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.</description>
        <time_frame>From 2 weeks after the last vaccine or placebo dose up to 1 year of age</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1496"/>
                  <measurement group_id="O2" value="1478"/>
                  <measurement group_id="O3" value="2974"/>
                  <measurement group_id="O4" value="1443"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strain</title>
            <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="26"/>
                  <measurement group_id="O3" value="56"/>
                  <measurement group_id="O4" value="70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain, Classified by Rotavirus Type</title>
        <description>Number of subjects presenting with three or more looser than normal stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.
Rotavirus types were G1 wild type (WT) and non-G1.</description>
        <time_frame>From 2 weeks after the last vaccine or placebo dose up to 1 year of age</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1496"/>
                  <measurement group_id="O2" value="1478"/>
                  <measurement group_id="O3" value="2974"/>
                  <measurement group_id="O4" value="1443"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain, Classified by Rotavirus Type</title>
            <description>Number of subjects presenting with three or more looser than normal stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.
Rotavirus types were G1 wild type (WT) and non-G1.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>G1 WT</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="17"/>
                  <measurement group_id="O4" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-G1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="39"/>
                  <measurement group_id="O4" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain</title>
        <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample.</description>
        <time_frame>From 2 weeks after the last vaccine or placebo dose up to 1 year of age</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1496"/>
                  <measurement group_id="O2" value="1478"/>
                  <measurement group_id="O3" value="2974"/>
                  <measurement group_id="O4" value="1443"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain</title>
            <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="93"/>
                  <measurement group_id="O2" value="74"/>
                  <measurement group_id="O3" value="167"/>
                  <measurement group_id="O4" value="174"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain</title>
        <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.</description>
        <time_frame>From the first vaccine or placebo dose up to 1 year of age</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1647"/>
                  <measurement group_id="O2" value="1651"/>
                  <measurement group_id="O3" value="3298"/>
                  <measurement group_id="O4" value="1641"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain</title>
            <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="68"/>
                  <measurement group_id="O4" value="83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In South Africa, Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain</title>
        <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.</description>
        <time_frame>From 2 weeks after the third dose of vaccine or placebo up to 1 year of age</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for efficacy, only for the subset of subjects in South Africa who were fully vaccinated before the beginning of the rotavirus season.
For this analysis, data from Rotarix 2-dose Group and Rotarix 3-dose Group were pooled into one group (Rotarix pooled Group).</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="478"/>
                  <measurement group_id="O2" value="468"/>
                  <measurement group_id="O3" value="946"/>
                  <measurement group_id="O4" value="468"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>In South Africa, Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain</title>
            <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Severe Gastroenteritis of Any Cause</title>
        <description>Number of subjects with gastroenteritis (three or more looser than normal stools or watery stools within a day) that scored ≥ 11 on the 20-point Vesikari scoring system.</description>
        <time_frame>From 2 weeks after the last vaccine or placebo dose up to 1 year of age</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1496"/>
                  <measurement group_id="O2" value="1478"/>
                  <measurement group_id="O3" value="2974"/>
                  <measurement group_id="O4" value="1443"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Severe Gastroenteritis of Any Cause</title>
            <description>Number of subjects with gastroenteritis (three or more looser than normal stools or watery stools within a day) that scored ≥ 11 on the 20-point Vesikari scoring system.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="134"/>
                  <measurement group_id="O2" value="122"/>
                  <measurement group_id="O3" value="256"/>
                  <measurement group_id="O4" value="178"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strain</title>
        <description>RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.</description>
        <time_frame>From 2 weeks after the last vaccine or placebo dose up to 1 year of age</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1496"/>
                  <measurement group_id="O2" value="1478"/>
                  <measurement group_id="O3" value="2974"/>
                  <measurement group_id="O4" value="1443"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strain</title>
            <description>RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="78"/>
                  <measurement group_id="O2" value="64"/>
                  <measurement group_id="O3" value="142"/>
                  <measurement group_id="O4" value="156"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strains</title>
        <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.</description>
        <time_frame>During the period from 2 weeks after the last dose of vaccine or placebo until study end</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for efficacy of the combined efficacy follow-up periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1873"/>
                  <measurement group_id="O4" value="891"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strains</title>
            <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3" value="81"/>
                  <measurement group_id="O4" value="66"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strains</title>
        <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.</description>
        <time_frame>During the period from 1 year of age to study end</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for efficacy of the second efficacy period.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1500"/>
                  <measurement group_id="O4" value="712"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strains</title>
            <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3" value="35"/>
                  <measurement group_id="O4" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Episode Caused by the Circulating Wild-type RV Strains</title>
        <description>RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.</description>
        <time_frame>During the period from 2 weeks after the last dose of vaccine or placebo until study end</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the ATP cohort for efficacy of the combined efficacy follow-up periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1873"/>
                  <measurement group_id="O4" value="891"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Episode Caused by the Circulating Wild-type RV Strains</title>
            <description>RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3" value="159"/>
                  <measurement group_id="O4" value="118"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Episode Caused by the Circulating Wild-type RV Strains</title>
        <description>RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.</description>
        <time_frame>During the period from 1 year of age to study end</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the ATP cohort for efficacy of the second efficacy period.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1500"/>
                  <measurement group_id="O4" value="712"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Episode Caused by the Circulating Wild-type RV Strains</title>
            <description>RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3" value="58"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strains, Classified by Rotavirus Type</title>
        <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.
Rotavirus types were G1 wild type (WT) and non-G1.</description>
        <time_frame>During the period from 2 weeks after the last dose of vaccine or placebo until study end</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the ATP cohort for efficacy of the combined efficacy follow-up periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1873"/>
                  <measurement group_id="O4" value="891"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strains, Classified by Rotavirus Type</title>
            <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.
Rotavirus types were G1 wild type (WT) and non-G1.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>G1 WT</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3" value="21"/>
                  <measurement group_id="O4" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-G1</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3" value="60"/>
                  <measurement group_id="O4" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strains, Classified by Rotavirus Type</title>
        <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.
Rotavirus types were G1 wild type (WT) and non-G1.</description>
        <time_frame>During the period from 1 year of age to study end</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the ATP cohort for efficacy of the second efficacy period.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1500"/>
                  <measurement group_id="O4" value="712"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strains, Classified by Rotavirus Type</title>
            <description>Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.
Rotavirus types were G1 wild type (WT) and non-G1.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>G1 WT</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-G1</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Adverse Events (AEs) or Serious Adverse Events (SAEs) Leading to Drop Out</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
        <time_frame>From the first dose of vaccine or placebo up to end of the study</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1647"/>
                  <measurement group_id="O2" value="1651"/>
                  <measurement group_id="O3" value="3298"/>
                  <measurement group_id="O4" value="1641"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Adverse Events (AEs) or Serious Adverse Events (SAEs) Leading to Drop Out</title>
            <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                  <measurement group_id="O2" value="54"/>
                  <measurement group_id="O3" value="111"/>
                  <measurement group_id="O4" value="56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
        <time_frame>From the first dose of vaccine or placebo up to end of the study</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1647"/>
                  <measurement group_id="O2" value="1651"/>
                  <measurement group_id="O3" value="3298"/>
                  <measurement group_id="O4" value="1641"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
            <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="222"/>
                  <measurement group_id="O2" value="199"/>
                  <measurement group_id="O3" value="421"/>
                  <measurement group_id="O4" value="246"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration of Anti-rotavirus Immunoglobulin A (IgA) Antibodies in Initially Seronegative Subjects</title>
        <description>An initially seronegative subject is a subject whose IgA antibody concentration was below the assay cut-off value of 20 Units per milliliter (U/mL) before administration of the first vaccine dose.</description>
        <time_frame>One month after the last vaccine dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for immunogenicity, only for initially seronegative subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="115"/>
                  <measurement group_id="O3" value="221"/>
                  <measurement group_id="O4" value="111"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Concentration of Anti-rotavirus Immunoglobulin A (IgA) Antibodies in Initially Seronegative Subjects</title>
            <description>An initially seronegative subject is a subject whose IgA antibody concentration was below the assay cut-off value of 20 Units per milliliter (U/mL) before administration of the first vaccine dose.</description>
            <units>Units per milliliter (U/mL)</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56.6" lower_limit="38.9" upper_limit="82.3"/>
                  <measurement group_id="O2" value="79.4" lower_limit="54.7" upper_limit="115.2"/>
                  <measurement group_id="O3" value="67.5" lower_limit="51.9" upper_limit="87.8"/>
                  <measurement group_id="O4" value="23.4" lower_limit="16.8" upper_limit="32.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects</title>
        <description>Seroconverted subjects are defined as subjects with appearance of anti-rotavirus IgA antibody concentration ≥ 20 U/mL in subjects initially (i.e. prior to the first dose of vaccine or placebo) seronegative for rotavirus.</description>
        <time_frame>One month after the last vaccine or placebo dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for immunogenicity, only for inititally seronegative subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="115"/>
                  <measurement group_id="O3" value="221"/>
                  <measurement group_id="O4" value="111"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroconverted Subjects</title>
            <description>Seroconverted subjects are defined as subjects with appearance of anti-rotavirus IgA antibody concentration ≥ 20 U/mL in subjects initially (i.e. prior to the first dose of vaccine or placebo) seronegative for rotavirus.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                  <measurement group_id="O2" value="72"/>
                  <measurement group_id="O3" value="129"/>
                  <measurement group_id="O4" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration of Anti-rotavirus Immunoglobulin A (IgA) Antibodies</title>
        <description>Geometric mean concentrations are given as Units per milliliter (U/mL).</description>
        <time_frame>One month after the last vaccine or placebo dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1160"/>
                  <measurement group_id="O2" value="1138"/>
                  <measurement group_id="O3" value="2298"/>
                  <measurement group_id="O4" value="1125"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Concentration of Anti-rotavirus Immunoglobulin A (IgA) Antibodies</title>
            <description>Geometric mean concentrations are given as Units per milliliter (U/mL).</description>
            <units>U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="72.5" lower_limit="65.2" upper_limit="80.6"/>
                  <measurement group_id="O2" value="67.9" lower_limit="60.8" upper_limit="75.9"/>
                  <measurement group_id="O3" value="70.2" lower_limit="65.0" upper_limit="75.8"/>
                  <measurement group_id="O4" value="21.8" lower_limit="19.8" upper_limit="24.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects</title>
        <description>Seropositive subjects are defined as subjects with anti-rotavirus IgA antibody concentration ≥ 20 U/mL.</description>
        <time_frame>One month after the last vaccine or placebo dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix 2-dose Group</title>
            <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O2">
            <title>Rotarix 3-dose Group</title>
            <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
          </group>
          <group group_id="O3">
            <title>Rotarix Pooled Group</title>
            <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1160"/>
                  <measurement group_id="O2" value="1138"/>
                  <measurement group_id="O3" value="2298"/>
                  <measurement group_id="O4" value="1125"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seropositive Subjects</title>
            <description>Seropositive subjects are defined as subjects with anti-rotavirus IgA antibody concentration ≥ 20 U/mL.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="756"/>
                  <measurement group_id="O2" value="706"/>
                  <measurement group_id="O3" value="1462"/>
                  <measurement group_id="O4" value="262"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rotarix 2-dose Group</title>
          <description>Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).</description>
        </group>
        <group group_id="E2">
          <title>Rotarix 3-dose Group</title>
          <description>Subjects received 3 doses of Rotarix™ (rotavirus vaccine).</description>
        </group>
        <group group_id="E3">
          <title>Rotarix Pooled Group</title>
          <description>For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group &amp; Rotarix 3-dose Group) were pooled into Rotarix pooled Group.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Group</title>
          <description>Subjects received 3 doses of placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="199" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="421" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="246" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Haemorrhagic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Heart disease congenital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Patent ductus arteriosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immunosuppression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="161" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="104" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Meningitis pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Acquired immunodeficiency syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Cerebral malaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Nosocomial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Parotid abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Viral tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Perianal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Keratitis herpetic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Salmonella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Brachial plexus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Fractured skull depressed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Pneumonitis chemical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Kwashiorkor</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Marasmus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Hyponatraemic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neuroblastoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Fontanelle bulging</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Grunting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Adenoidectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3298"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1641"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
